Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Press Release

Zanda’s cattle pain relief vision on show

September 27, 2017

IT’S a matter of seeing is believing. A squirt of the blue gel from the purpose made applicator onto the wounds left by the dehorning, branding or, in the case of bull calves, castration, and the job is done.

But it’s the behaviour of those young calves almost immediately after leaping up from the branding cradle that is perhaps the most impressive. Despite having just undergone these invasive animal husbandry practices, only minutes later they stand with their mates appearing calm and relaxed.

There is no headshaking, no calves lying down, and no obvious distress. Most impressive is there is no visible bleeding. In fact, because of the barrier the blue gel creates across the entire wound, it is hard to even see the wound.

For major pastoral company MDH, the use of the Bayer pain relief product Trisolfen on its Cloncurry property, Devoncourt, is as an integral part of its husbandry practices at branding. Partly because it reduces the stress imposed on the young animals, partly because it helps guard against infection, and partly because it is part of bigger picture of ensuring that on-farm animal husbandry practices are inline with consumers expectations.

Mount Isa-based vet Ed Butterworth, North West Veterinary Clinic, who helps oversee the 170,000 head MDH herd is clearly impressed with the effectiveness of the now commercially available pain relief product.

“It’s easy to use and obviously effective,” Dr Butterworth said.

“The behaviour of the calves suggests they are obviously under less stress once the pain relief has been applied.”

Initially developed to provide pain relief for lambs after mulesing, Trisolfen is a pain relieving and wound healing formulation that has short term and long term analgesia, antiseptics, reduces blood loss and coats the wound. It costs between about a $1 and $1.50 to treat each animal. It is described as best suited to calves aged six to eight weeks and is designed to provide pain relief for 24 to 36 hours. Bayer, which manufactures Trisulfen under license from Animal Ethics, has formulated a thicker gel that has an 18 month shelf life.

Alistair McDonald said MDH was likely use Trisolfen on all of the more than 40,000 calves from next year, pending final registrations. “The benefits to the calves from Trisolfen are obvious and significant,” Mr McDonald said. “Since we started the trial work in 2012 we’ve been working out the best way to use the product. It really takes away the stress and the calves are looking for a drink within minutes.”

MDH uses Angus bulls as terminal sires over high grade Brahman females on Devoncourt. The majority of the cattle bred by MDH are fed through the company’s Wallumba Feedlot at Condamine.

Mark Phelps flew with Pilatus Australia, in recognition of the late Zanda McDonald, who helped initiate theTrisolfen trial work.

Why pain relief really matters

IT WAS borne from the recognition that the livestock industry needed to stay ahead of the game. A kitchen table conversation between forward thinking Cloncurry-based pastoralist, the late Zanda McDonald, and industry leader Chick Olsson more than 10 years ago questioned how the beef industry could ensure the continued use of essential husbandry practices including dehorning, castration and branding.

Disturbed by the ongoing and damaging campaign launched by US-based extreme animal rights group PETA on the wool industry and its use of mulesing, the pair recognised that the beef industry was potentially open to attack.

Regardless of how important the practices were ultimately to an animal’s long term welfare, conventional husbandry practices – particularly those that involved invasive surgery – could easily be misconstrued by activist groups campaigning to destroy consumer confidence in the $17 billion industry.

Part of the solution lay in providing pain relief that was both effective and able to be applied in difficult environment presented by busy and dusty cattle yards. Enter Trisolfen, a product developed by Animal Ethics, a company owned by Mr Olsson and other keen investors determined to counter PETA’s attack on Australian wool. The antiseptic gel now licensed to Bayer Trisolfen is a pain relieving and wound healing formulation that has short term and long term analgesia, antiseptics, reduces blood loss and coats the wound.

“When PETA started campaigning against mulesing, US retailers of Australian wool began dropping like flies,” Mr Olsson said. “The industry could fight PETA all it wanted and argue that mulesing was essential, but the reality was retailers were refusing to sell Australian wool and increasing numbers of consumers were refusing to buy Australian wool.

“Until the use of pain relief became widespread, PETA was winning and the only losers were Australian woolgrowers. Zanda could see a potentially similar problem emerging for the beef industry. We needed to be proactive and ensure the way we produce beef is in line with consumer expectations about how animals are treated.”

Further information

Medical Ethics

Allan Giffard, Managing Director
+61 419 362 286

FTI Consulting

Sydney, Australia:
Celia Moore
+61 432 344 069

London, UK:
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000